Picture loading failed.

Anti-FGF23 therapeutic antibody (Pre-made Burosumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Burosumab (INN, sold under the brand name Crysvita) is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.[ Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018.[8] The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-086-1mg 1mg 3090
GMP-Bios-ab-086-10mg 10mg 21890
GMP-Bios-ab-086-100mg 100mg 148000
GMP-Bios-ab-086-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-FGF23 therapeutic antibody (Pre-made Burosumab biosimilar,Whole mAb)
INN Name Burosumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesKyowa Hakko Kirin;Ultragenyx Pharmaceutical
Conditions ApprovedX-linked dominant hypophosphataemic rickets;Osteomalacia
Conditions ActiveNevus
Conditions Discontinuedna
Development Techna